The competitive outlook for a key therapy is worrying investors.
News & Analysis: Amicus Therapeutics
Investor concerns over the competitive outlook for the company's Pompe disease therapy candidate weighed on its stock price.
FOLD earnings call for the period ending June 30, 2019.
Amicus' shares shot up by 10.7% last month. Here's why.
Earnings and other concerns held some stocks back Thursday.
The company announced a significant stock offering.
Amicus Therapeutics and Array BioPharma are two top growth stocks to consider buying now.
FOLD earnings call for the period ending March 31, 2019.
These growth companies could make a killing if their big bets pay off.
FOLD earnings call for the period ending December 31, 2018.